Treatment
Imatinib clinical trials
We’re tracking 35 recruiting studies that include Imatinib, each written for real people, not researchers, below.
Recruiting studies
- NCT03844360RecruitingPhase 4
Personalized dosing of cancer or infection medicines in children
This trial looks at how to adjust the dose of cancer medicines and/or anti-infection medicines in children who have blood-related cancers. The goal is to make dosing fit each child’s needs while they receive standard treatment.
Xuzhou, JiangsuAges 1 day–18 years - NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
Phoenix, ArizonaAges 18 years+ - NCT06917196Recruiting
Inhaled imatinib for advanced lung disease before or after transplant
This trial tests whether a special inhaled form of the medicine imatinib can help people with advanced lung scarring or high blood pressure in the lungs. It is designed for those who are on the path to a lung transplant or already received one.
Pavia, PaviaAges 18 years+ - NCT07096609RecruitingPhase 1/Phase 2
Lenvatinib for GIST after imatinib, sunitinib, and regorafenib
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
SeoulAges 20 years+ - NCT06889168RecruitingPhase 1
Long-term safety of imatinib for LAM
This study tests the long-term safety and tolerability of the drug imatinib in women with LAM, a rare lung disease that causes cysts. It may help stabilize lung function over time.
New York, New YorkAges 18–64 - NCT06682169RecruitingPhase 3
New pill for chronic graft-versus-host disease after other treatments fail
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
Hefei, AnhuiAges 18–70 - NCT04877522RecruitingPhase 4
Continued asciminib treatment for certain leukemia patients
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
Ann Arbor, MichiganAges 7–100 - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT04307576RecruitingPhase 3
Study for newly diagnosed ALL children and young adults
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
BrusselsAges birth–45 years - NCT01746836RecruitingPhase 2
Ponatinib for CML that didn’t respond to prior pills
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
Houston, TexasAges 18 years+ - NCT00816114Recruiting
Chart review for CML patients previously treated with certain pills
This study reviews existing medical records of people with chronic myelogenous leukemia (CML) who were treated with specific FDA-approved targeted tablets (tyrosine kinase inhibitors) at MD Anderson but not on an MD Anderson clinical trial. It may help the hospital understand how these medicines are used in real-world care.
Houston, TexasAges Any age
Common questions
- Are there clinical trials studying Imatinib?
- Yes. Clin2 currently lists 35 recruiting studies that include Imatinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Imatinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Imatinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Imatinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.